Amol Akhade: ESMO Presidential Today – Keynote 522 Shows Overall Survival

Amol Akhade shared a post on LinkedIn:

”ESMO presidential today.

Keynote 522 shows overall survival (OS) – positive trial.

Questions remains:

1. Can we avoid adjuvant Pembrolizumab in those who get PCR post NACT ?
2. Can we have biomarkers to predict this ?
3. Can we have less duration of adjuvant Pembrolizumab ?
4. Do we need to do something more for those who don’t get PCR ?

Slides for those who missed it Live.”

Source: Amol Akhade/LinkedIn

Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.